Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Glofitamab plus Polatuzumab-R-CHP for the Treatment of High-Risk Diffuse Large B-Cell Lymphoma

Trial Status: active

This phase II trial tests how well glofitamab in combination with polatuzumab and a standard chemotherapy regimen (rituximab, cyclophosphamide, doxorubicin hydrochloride [hydroxydaunomycin], and prednisone) works in treating patients with high-risk diffuse large B-cell lymphoma. Glofitamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread by binding to CD20, an antigen commonly expressed by B-cell cancers. Polatuzumab vedotin is a monoclonal antibody, called polatuzumab, linked to a chemotherapy drug, called vedotin. Polatuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD20 receptors, and delivers vedotin to kill them. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell’s deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body’s immune response. Other chemotherapy drugs, such as doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Giving glofitamab in combination with polatuzumab and standard chemotherapy may help treat patients with high-risk diffuse large B-cell lymphoma.